<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743272</url>
  </required_header>
  <id_info>
    <org_study_id>LMSRR</org_study_id>
    <nct_id>NCT03743272</nct_id>
  </id_info>
  <brief_title>Repeatability and Reproducibility of Multiparametric MRI</brief_title>
  <official_title>Repeatability and Reproducibility of Multiparametric MRI (LiverMultiScan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perspectum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perspectum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to prospectively assess the repeatability and reproducibility of&#xD;
      iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification&#xD;
      with multiparametric MRI using the LiverMultiScan™ (LMS, Perspectum Diagnostics, Oxford, UK)&#xD;
      protocol across different field strengths, scanner manufacturers and models.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the burden of liver disease reaches epidemic levels, there is a high unmet medical need to&#xD;
      develop robust, accurate and reproducible non-invasive methods to quantify liver tissue&#xD;
      characteristics for use in clinical development and ultimately in clinical practice.&#xD;
      Repeatability and reproducibility validation studies are important in evaluating metrics,&#xD;
      such that any changes can be confidently attributed to disease progression or regression,&#xD;
      rather than inter-examination variability in the instrument.&#xD;
&#xD;
      Magnetic resonance (MR) techniques offer an attractive non-invasive option for liver&#xD;
      assessment. Multiparametric MRI is a safe and non-invasive method for quantification of liver&#xD;
      tissue characteristics. Images for quantification of hepatic fat from proton density fat&#xD;
      fraction (PDFF) maps, T2*, and iron-corrected T1 (cT1) can be rapidly obtained during&#xD;
      abdominal breath-hold acquisitions without the need for contrast agents or additional&#xD;
      external hardware. Iron correction of T1 is necessary to address the confounding effects of&#xD;
      excess iron, which is common in chronic liver disease. LiverMultiScan™ (LMS, Perspectum&#xD;
      Diagnostics, Oxford, UK) is a software application that can be used with supported MR-systems&#xD;
      to correct T1 for the effects of excess iron, and thus, to calculate cT1 from T1 and T2*&#xD;
      maps, and standardise to a 3T field strength.&#xD;
&#xD;
      This method has been shown to have high diagnostic accuracy for the assessment of liver&#xD;
      fibrosis compared to histology, predict clinical outcomes in patients with mixed liver&#xD;
      disease aetiology, stratify patients with non-alcoholic steatohepatitis (NASH) and cirrhosis,&#xD;
      reliably exclude clinically significant liver disease and is cost-effective in diagnosing&#xD;
      NAFLD.&#xD;
&#xD;
      In addition to demonstrating accuracy, imaging biomarker validation requires precision and&#xD;
      repeatability (US Department of Health and Human Services, 2015). From a clinical&#xD;
      perspective, it is essential to ensure that there is good inter-examination repeatability, so&#xD;
      that any changes seen can be correctly attributed to disease progression or regression,&#xD;
      rather than inter-examination variability. This is tested by examining the closeness of&#xD;
      repeated measurements made in different MR examinations (with both subject and coil&#xD;
      repositioning) over a time frame in which physiologic conditions are assumed constant.&#xD;
&#xD;
      This study aims to systematically test the repeatability and reproducibility of each&#xD;
      multiparametric MRI measurement, cT1, T2* and PDFF, corresponding to hepatic&#xD;
      fibro-inflammation, iron and fat respectively, across scanner field strength, manufacturer&#xD;
      and model in human participants and phantoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Repeatability</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of multi-parametric MRI measures (MRI-PDFF, T2* and iron-corrected T1 (cT1)) from repeated acquisitions of the same participant on the same scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reproducibility</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of multi-parametric MRI measures (MRI-PDFF, T2* and iron-corrected T1 (cT1)) from repeated acquisitions of the same participant on different scanners (1.5T and 3.0T).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Liver Diseases</condition>
  <condition>Primary Biliary Cirrhosis</condition>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <condition>Cirrhosis</condition>
  <condition>Hemochromatosis</condition>
  <condition>Viral Hepatitis</condition>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Liver condition</arm_group_label>
    <description>Participants who have a history of of liver disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Participants who have do not have a diagnosed liver condition and are in general good health</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LiverMultiScan</intervention_name>
    <description>Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Liver condition</arm_group_label>
    <other_name>Multiparametric Magnetic Resonance Imaging (mpMRI)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are those with mixed liver disease aetiology and those without any history of&#xD;
        liver disease in order to represent a wide range of values of hepatic fat, iron, and&#xD;
        fibro-inflammatory status.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any person over 18 years of age.&#xD;
&#xD;
          -  Participant is willing and able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant may not enter the study if they have any contraindication to magnetic&#xD;
             resonance imaging (inc pregnancy, extensive tattoos, pacemaker, shrapnel injury,&#xD;
             severe claustrophobia).&#xD;
&#xD;
          -  Any other cause, including a significant disease or disorder which, in the opinion of&#xD;
             the investigator, may either put the participant at risk because of participation in&#xD;
             the study or affect the participant's ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajarshi Banerjee, BM BCh MS DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Perspectum Diagnostics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soubera Rymell, BSc</last_name>
    <phone>+441865655343</phone>
    <email>soubera.rymell@perspectum.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Velicia Bachtiar, DPhil</last_name>
    <phone>+441865655343</phone>
    <email>velicia.bachtiar@perspectum-diagnostics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR)</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Lacey</last_name>
      <phone>+441865220245</phone>
      <email>kathryn.lacey@cardiov.ox.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiparametric MRI</keyword>
  <keyword>LiverMultiScan</keyword>
  <keyword>Repeatability</keyword>
  <keyword>Reproducibility</keyword>
  <keyword>Liver MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
    <mesh_term>Hemochromatosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

